Trial Profile

Cambridge Brain Mets Trial 1: A proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low dose, targeted radiotherapy

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Corticosteroids
Indications Advanced breast cancer; Brain metastases; Lung cancer; Male breast cancer
Focus Pharmacokinetics; Proof of concept
Acronyms CamBMT1

30 Jan 2024 Status changed from recruiting to discontinued.
12 Jan 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Jun 2021.
12 Dec 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com